These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 19215786)
1. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786 [TBL] [Abstract][Full Text] [Related]
2. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134 [TBL] [Abstract][Full Text] [Related]
3. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939 [TBL] [Abstract][Full Text] [Related]
4. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Jaffe JM; Malkowicz SB; Walker AH; MacBride S; Peschel R; Tomaszewski J; Van Arsdalen K; Wein AJ; Rebbeck TR Cancer Res; 2000 Mar; 60(6):1626-30. PubMed ID: 10749132 [TBL] [Abstract][Full Text] [Related]
5. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801 [TBL] [Abstract][Full Text] [Related]
6. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774 [TBL] [Abstract][Full Text] [Related]
7. [Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer]. Tong M; Xu Z; Ai JK; Yuan YM; Yin Y; Wang JQ; Li HW; Liu JH; Xin DQ; Zhou LQ; Li M; Na YQ Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(24):1493-6. PubMed ID: 15733480 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Chang BL; Zheng SL; Isaacs SD; Turner AR; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J Prostate; 2003 Jun; 56(1):37-44. PubMed ID: 12746845 [TBL] [Abstract][Full Text] [Related]
9. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148 [TBL] [Abstract][Full Text] [Related]
10. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294 [TBL] [Abstract][Full Text] [Related]
11. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk. Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111 [TBL] [Abstract][Full Text] [Related]
12. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447 [TBL] [Abstract][Full Text] [Related]
13. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Mononen N; Ikonen T; Syrjäkoski K; Matikainen M; Schleutker J; Tammela TL; Koivisto PA; Kallioniemi OP Br J Cancer; 2001 May; 84(10):1344-7. PubMed ID: 11355945 [TBL] [Abstract][Full Text] [Related]
14. [Association between A49T polymorphism of SRD5A2 gene and risk of prostate cancer]. Tong M; Ai JK; Yuan YM; Yin Y; Zhou LQ; Xin DQ; Li M; Na YQ Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1319-21. PubMed ID: 16029630 [TBL] [Abstract][Full Text] [Related]
15. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis. Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631 [TBL] [Abstract][Full Text] [Related]
16. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593 [TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840 [TBL] [Abstract][Full Text] [Related]
18. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Ntais C; Polycarpou A; Ioannidis JP Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400 [TBL] [Abstract][Full Text] [Related]
19. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K J Androl; 2009; 30(6):703-10. PubMed ID: 19443907 [TBL] [Abstract][Full Text] [Related]
20. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer]. Liu JH; Li HW; Tong M; Li M; Na YQ Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]